RDH16

Across TCGA pan-cancer cohorts, RDH16 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RDH16 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RDH16 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RDH16 expression acts as an unfavorable survival marker.

HNSC and LSCC are the cancer types where RDH16 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.737	0.990	.027	3	view →
LSCC	DFS	Median	II,III,IV	0.516	0.803	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RDH16–HNSC (OS)

Open the HNSC breakdown →